LGALS1 and familial pancreatic carcinoma: Embracing advances in molecular biology, nanotechnology, and precision medicine with a central focus on Gal-1 will be paramount in charting new therapeutic avenues, ultimately aiming to revolutionize pancreatic cancer management.